Colfax Corporation (CFX)

LAKEWOOD, Colo. , Oct. 2, 2024 /PRNewswire/ -- Natural Grocers® announces plans to close its Downtown Denver store located at the corner of Colfax and Washington, on October 31, 2024.

Enovis (NYSE:ENOV – Get Free Report) and Envoy Medical (NASDAQ:COCH – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership. Analyst Recommendations This is a breakdown of current ratings and target prices for Enovis and Envoy Medical, as reported by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enovis 0 0 8 0 3.00 Envoy Medical 0 0 2 0 3.00 Enovis presently has a consensus target price of $75.43, indicating a potential upside of 43.92%. Envoy Medical has a consensus target price of $6.00, indicating a potential upside of 92.93%. Given Envoy Medical’s higher possible upside, analysts clearly believe Envoy Medical is more favorable than Enovis. Institutional and Insider Ownership 98.5% of Enovis shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 2.4% of Enovis shares are owned by insiders. Comparatively, 0.7% of Envoy Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Volatility & Risk Enovis has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Profitability This table compares Enovis and Envoy Medical’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Enovis -4.51% 3.98% 2.88% Envoy Medical N/A N/A -112.11% Valuation and Earnings This table compares Enovis and Envoy Medical’s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $1.71 billion 1.68 -$33.26 million ($1.50) -34.94 Envoy Medical $316,000.00 192.90 -$29.91 million N/A N/A Envoy Medical has lower revenue, but higher earnings than Enovis. Summary Enovis beats Envoy Medical on 6 of the 11 factors compared between the two stocks. About Enovis (Get Free Report) Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware. About Envoy Medical (Get Free Report) Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

NEW YORK , March 30, 2022 /PRNewswire/ -- ESAB Corp. (NYSE: ESAB) will be added to the S&P MidCap 400 effective prior to the opening of trading on Tuesday, April 5. Effective prior to the opening of trading on Wednesday, April 6, S&P MidCap 400 constituent PROG Holdings Inc. (NYSE: PRG) will replace Fiesta Restaurant Group Inc. (NASD: FRGI) in the S&P SmallCap 600.

Colfax Corp's (NYSE: CFX) price target has been lowered to $52 (an upside of 41%) from $60 by KeyBanc analyst Jeffrey Hammond, following ESAB/Enovis's 2022 Investor Day to reflect broadly lower peer multiples. The analyst maintained an Overweight rating on CFX.

Colfax's (CFX) fourth-quarter 2021 net sales increase 23.6% year over year on impressive performance across its segments.

Colfax Corporation (CFX) CEO Matt Trerotola on Q4 2021 Results - Earnings Call Transcript

Colfax (CFX) delivered earnings and revenue surprises of 3.51% and 2.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Colfax (CFX) is poised to benefit from its exposure in diverse end markets, acquired assets and solid demand for its products. However, rising costs and high debt levels remain concerns.

Colfax (CFX) benefits from solid product offerings and focus on innovation, healthy demand and acquisition synergies. Cost inflation and supply-chain woes are concerning.

Wilmington, DE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, announced today that it will be presenting at the J.P. Morgan Healthcare Conference on January 12, at 3:00 pm (EST).  A live presentation of this event will be available via Colfax's website at  www.colfaxcorp.com  under the “Investors” section. Replays will also be available on the Company's website following the event.

Sharp sell-offs can reveal great stock ideas if you surface the right stocks that contrary to the market action close positive. When picking names that close in the green, make sure they are well known and of a higher market cap. They tend to have sustainable rallies when they turn around.

Colfax Corporation's (CFX) CEO Matt Trerotola on Q3 2021 Results - Earnings Call Transcript

Colfax's (CFX) Q3 earnings reflect the impacts of improved sales, margin expansion, supply-chain woes and logistics issues. For 2021, it lowers earnings projections on high taxes and pandemic woes.

Colfax (CFX) delivered earnings and revenue surprises of 0.00% and 1.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Colfax Corp (NYSE: CFX) reported third-quarter sales growth of 20% year-over-year to $965.89 million, +15% on an organic sales-per-day basis, beating the consensus of $958.430 million. Adjusted EPS improved to $0.54 from $0.41 in 3Q20, beating the consensus of $0.53.